Leiden Bio Science Park

Laboratory and process technology at Skills Masters event for (v)mbo students and persons seeking for employment

2010-03-10 15:07:57 +0100

At the 4th, 5th and 6th of March, the Leiden Bio Science Park cooperated with a diversity of companies, knowledge centers and branch organizations in presenting laboratory and process technology at Skills Masters.

Information Session on Dutch Life Science week at World Expo in Shanghai

2010-03-10 12:11:56 +0100

On March 25, from 15 hrs on, there will be an information session on the Dutch Life Science week at World Expo in Shanghai. If you are considering to join this meeting, please register at info@coinnovation.net.

Are you a pharmaceutical innovator? Need more intelligence?

2010-03-10 12:03:16 +0100

Join the demonstration session of Thomsom Pharma, organised by Life Science & Health at their premises in Leiden on March 25th. LSH managed to negotiate a reduced fee for SME’s to benefit from competitive intelligence. To join this meeting you can respond to Annemiek Verkamman.

OctoPlus publishes prospectus for listing of shares issued on 18 December 2009

2010-03-08 15:37:55 +0100

OctoPlus N.V. published a prospectus for the admission to listing and trading on Euronext Amsterdam by NYSE Euronext of 211,806 newly issued ordinary shares as per 9 March 2010.

Galapagos reports record revenues and net profit for 2009, foresees sustained profitability

2010-03-05 10:02:10 +0100

• Total revenues of €106 M (+34%) • Group net profit of €3 M • R&D revenues of €63.8 M (+76%), driven by alliances • BioFocus recurrent segment profit of €7.9 M (+174%) • Cash position of €47.4 M at year-end • Four programs moved into clinical development • 2010 guidance: profitability and positive cash-flow, revenues more than €135 million

to-BBB and GSK to collaborate on brain delivery of a biologic product

2010-03-03 15:21:33 +0100

to-BBB, the Dutch brain drug delivery company announced that it has entered into a research collaboration with GlaxoSmithKline (GSK) involving to-BBB’s proprietary G-Technology® in delivering a biological compound to the brain.

Syntarga Announces Two Antibody-Drug Conjugate Collaborations

2010-03-03 00:00:00 +0100

Syntarga B.V., the emerging Antibody-Drug Conjugate (ADC) company, announced today that it entered into research collaborations with two undisclosed top-15 pharma companies.

Universal Biotech Innovation Grant 2010

2010-03-03 00:00:00 +0100

Registration is now open for application for the Universal Biotech Innovation Prize 2010. A Grant up to 100 000 euros will be shared by two or three winners. This grant rewards the best innovation within the areas innovative therapy and diagnostic products.

Dutch Space provides solar arrays for Sentinel satellites

2010-02-23 00:00:00 +0100

Dutch Space, leading space company in the Netherlands, has been granted two new contracts for the delivery of solar panels for the Sentinel-1 and Sentinel-2 satellites.

WFIA: 2009 succesful year for acquisition of foreign companies

2010-02-23 00:00:00 +0100

Despite the worldwide economic crisis, in 2009 the WestHolland Foreign Investment Agency managed to acquire 35 international projects to the region The Hague, Delft, Leiden and Zoetermeer. Compared to 2008 this is an increase of seven companies.
> Read more in Dutch

Galapagos successfully completes Phase I clinical trials for rheumatoid arthritis candidate drug GLPG0259

2010-02-23 00:00:00 +0100

Galapagos NV announced that it has completed Phase I clinical trials for GLPG0259, a novel mechanism-of-action candidate drug being developed for rheumatoid arthritis (RA).

Galapagos delivers third candidate drug in GSK alliance, receives �5.7 million

2010-02-22 00:00:00 +0100

Galapagos NV announced that it has successfully identified a third candidate drug in its arthritis alliance with GlaxoSmithKline.

Pharming Announces 2009 Results

2010-02-18 15:15:47 +0100

Biotech company Pharming Group NV announced its preliminary results for the year ended December 31, 2009.

Galapagos and MorphoSys expand antibody alliance

2010-02-18 00:00:00 +0100

Galapagos NV (Euronext: GLPG) and MorphoSys AG (FSE: MOR) announce that they have expanded their antibody alliance in bone & joint diseases.

CHDR Newsletter Spring 2010

2010-02-17 11:49:42 +0100

Click here to read the latest edition of the CHDR Newsletter.

BAC Extends Partnership with GE Healthcare to Launch Alpha-1 Antitrypsin Select

2010-02-17 11:45:10 +0100

BAC BV, the leading provider of antibody-based affinity purification technology, has extended its collaboration with GE Healthcare with the addition of a new bioprocess affinity chromatography ligand to GE Healthcare’s range of custom designed media.

Pharming�s C1 Inhibitor Product potentially effective In reducing complications following transplantation

2010-02-17 00:00:00 +0100

Biotech company Pharming Group NV announced publication of preclinical evidence that its recombinant human C1 inhibitor (rhC1INH) may play an important therapeutic role in the prevention of delayed graft function (DGF) after solid organ transplantation.

Leiden Bio Sience Park only mature science park in West Holland

2010-02-15 00:00:00 +0100

Only four out of the fiftyfive innovative campuses in the Netherlands are in a mature stage. Most campuses turn out to be common business parks or just a plan.

> Read more in Dutch

Centocor staff graduate from ROC (Regional Vocational Training)

2010-02-15 00:00:00 +0100

On Monday 15 February, seven Centocor staff members were awarded their medical laboratory assistant’s diploma from the MLO (Medical Laboratory Assistant’s Course) at the ROC Leiden.

Genencor Introduces a breakthrough enzyme product for cellulosic biofuels development

2010-02-15 00:00:00 +0100

Genencor, a division of Danisco A/S, introduced Accellerase® DUET at the Renewable Fuels Association’s 15th Annual National Ethanol Conference in Orlando, Florida (USA).

Dutch public-private partnership invests 28 million Euro in research into personalized medicine

2010-02-15 00:00:00 +0100

The Netherlands' three Top Institutes for life-science research (the BioMedical Materials program, the Center for Translational Molecular Medicine and Top Institute Pharma) announced a joint investment of M€ 28 on innovative research targeted at bringing personalized medicine closer to reality.

Collective Holland Lounge at the international healthcare exhibition Exposanità in Bologna, Italy

2010-02-11 00:00:00 +0100

Initiated by the EVD and in collaboration with the Chamber of Commerce Brabant, Health Valley and Consobiomed, May 26 to May 29, Exportimpulse organizes a Holland Lounge (40 m2) for max 15 companies at Exposanita.

> Read more in Dutch

OctoPlus announces that Locteron interim Phase IIb data have been accepted for oral and poster presentations at International Liver Congress in April

2010-02-10 00:00:00 +0100

OctoPlus N.V. announced that its licensee Biolex Therapeutics (see separate Biolex press release on www.biolex.com) has been accepted to present interim results from two ongoing Phase IIb studies with Locteron® at the 45th Liver Congress on 14 -18 April 2010 in Vienna, Austria.

Crucell Announces Record Revenues and Profits for Full Year 2009

2010-02-09 17:26:27 +0100

Total revenues and other operating income increased 26% to €358.0 million. Operating profit increased more than four-fold to €39.0 million. Net profit increased 68% to €23.9 million. Undiluted EPS increased 55% to €0.34. Year-end cash and short-term liquidities €428.0 million.

Arnoud van Tulder nieuwe CEO Cryo-Save Group

2010-02-04 09:52:40 +0100

Cryo-Save Group N.V. (AIM/Euronext: CRYO, “Cryo-Save” of “de Groep”), de grootste stamcelbank van Europa, kondigt aan dat Arnoud van Tulder (48), momenteel Chief Financial Officer van de Groep, met ingang van 1 mei 2010 zal worden benoemd tot Chief Executive Officer. Arnoud van Tulder zal Marc Waeterschoot (60) opvolgen, die evenwel aanblijft als Executive Director in de Board of Directors.